Stocks Health care ASND
NASDAQ · Health careAscendis Pharma A/S (ASND)
Ascendis Pharma A/S reported revenue of €720.1M in fiscal 2025, up 98.0% from a year earlier. It posted a net loss of €228M. At December 31, 2025 it held €616M in cash against €720.3M of debt.
What Ascendis Pharma A/S does
Ascendis Pharma A/S is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ASND.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | €720.1M | -€228M | -€3.76 | n/a |
| 2024 | €363.6M | -€378.1M | -€6.53 | n/a |
| 2023 | €266.7M | -€481.4M | -€8.55 | -€469.8M |
| 2022 | €51.2M | -€583.2M | -€10.40 | -€510.2M |
| 2021 | €7.8M | -€383.6M | -€7.00 | -€441.4M |
| 2020 | €7M | -€419M | -€8.28 | -€291.4M |
Latest SEC filings
What Ascendis Pharma A/S has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 15, 2026
- September 15, 2026
- September 9, 2026
- September 9, 2026
- August 31, 2026
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026
- August 13, 2026
- August 12, 2026
- August 6, 2026
Questions about ASND
What does Ascendis Pharma A/S do?
Ascendis Pharma A/S is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ASND.
Is Ascendis Pharma A/S profitable?
No. In fiscal 2025 it reported a net loss of €228M on revenue of €720.1M.
How much revenue does Ascendis Pharma A/S make?
In fiscal 2025 Ascendis Pharma A/S reported revenue of €720.1M. That is 98.0% more than a year earlier.
When did Ascendis Pharma A/S last report?
Its newest filing of any kind is the foreign issuer update from September 15, 2026.
Similar companies
Follow ASND
Get an email when Ascendis Pharma A/S files with the SEC: results, executive changes, material agreements and annual reports.
Follow ASND: get an email when it filesWhere the numbers come from
Financial figures are the values Ascendis Pharma A/S tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.